+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023 - Product Image

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2019-2023

  • ID: 4825193
  • Report
  • August 2019
  • Region: Global
  • 111 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market: About this market

BCL-2 inhibitors are used as a targeted therapy to treat cancer by blocking the BCL-2 protein. The BCL-2 inhibitors market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales of BCL-2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as label expansion of venetoclax from monotherapy to combination therapy and high efficacy and tolerability of combination therapy compared with monotherapy will significantly help the market segment in maintaining its leading position. Also, our global BCL-2 inhibitors report has observed market growth factors such as rise in geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors. However, the availability of substitutes, adverse effects of BCL-2 inhibitors, and drug resistance may hamper the growth of the BCL-2 inhibitors industry over the forecast period.

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market: Overview

Growing awareness about hematological malignancies

Most of the times, symptoms of hematological malignancies are mild or not apparent. This may hamper the market growth as the patient may not know how to identify symptoms and opt to visit a specialist. To combat this challenge, many organizations and market vendors have been organizing awareness programs to educate patients about indication symptoms and available diagnostic methods and treatment options. These awareness programs also conduct cancer screening. As a result, appropriate diagnosis and treatment will take place. This will increase sales of BCL-2 inhibitors, which will lead to the expansion of the BCL-2 inhibitors market at a CAGR of almost 39% during 2019-2023.

Development of novel formulations

The only approved therapy available in the market to treat hematological malignancies is venetoclax, which has limited anti-BCL activity. Therefore, vendors have started formulating novel drugs that can be administered in combination with other therapies. These novel drugs are formulated to overcome drug resistance caused by BCL-2 inhibitors and provide enhanced efficacy. As a result, this trend will have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global BCL-2 inhibitors market is concentrated. The robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading BCL-2 inhibitors manufacturers, which include AbbVie Inc. and F. Hoffmann-La Roche Ltd.

Also, the BCL-2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increase of patient assistance programs
  • Strategic alliances
  • Development of novel formulations
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Some of the approved combination therapies
Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Prevalence, incidence, and mortality in the US are tabulated as follows.
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: AbbVie Inc. - Vendor overview
Exhibit 47: AbbVie Inc. - Business segments
Exhibit 48: AbbVie Inc. - Organizational developments
Exhibit 49: AbbVie Inc. - Geographic focus
Exhibit 50: AbbVie Inc. - Key offerings
Exhibit 51: AbbVie Inc. - Key customers
Exhibit 52: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 53: F. Hoffmann-La Roche Ltd. - Product segments
Exhibit 54: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 55: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 56: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 57: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 58: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 59: Validation techniques employed for market sizing
Exhibit 60: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE
The following companies are recognised as the key players in the global BCL-2 inhibitors market: AbbVie Inc. and F. Hoffmann-La Roche Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel formulations.”

According to the report, one of the major drivers for this market is the growing awareness about hematological malignancies.

Further, the report states that one of the major factors hindering the growth of this market is the availability of substitutes.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll